Pharmafile Logo
Pharmafocus logo
Advanced Search

Esbriet

Showing 15 posts of 18 posts found.

roche__tree

NICE rejects expanded treatment indication for Roche’s Esbriet

September 19, 2016
Sales and Marketing Esbriet, NICE, Roche, rejection

NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …

News
boehringer_good

Boehringer launches IPF initiatives

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Boehringer Ingelheim, Esbriet, Roche, idiopathic pulmonary fibrosis, ofev

Boehringer Ingelheim has launched a collaborative initiative aimed at raising awareness and understanding of the rare lung disease Idiopathic Pulmonary …

News
roche_glass_building

Roche beats estimates with strong 2015 sales

January 28, 2016
Medical Communications, Sales and Marketing Esbriet, Herceptin, Roche, avastin

Roche reported full-year financial results today, beating analysts’ estimates, with the Swiss drugmaker announcing Group sales increases for 2015 in …

News

Roche says Esbriet shown to extend lives of IPF patients

September 30, 2015
Medical Communications, Research and Development, Sales and Marketing Esbriet, Roche, idiopathic pulmonary fibrosis

Roche has presented new clinical data and abstracts on Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF), showing …

News
Esbriet

Roche to present new Esbriet data at ERS Congress 2015

September 21, 2015
Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone

Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …

News

Boehringer widens IPF drug’s reach

May 18, 2015
Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev

Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …

News
Roche image

Roche buoyed by cancer drug sales

April 22, 2015
Sales and Marketing Actemra, Cancer, Esbriet, Esbriet., MabThera, Q1, Rituxan, RoActemra, Roche, Xolair, avastin, oncology

Pharma’s biggest cancer drugs maker Roche has reported strong sales growth on the back of its oncology portfolio for its …

News
Ofev image

Boehringer eyes Ofev success in IPF and beyond

March 16, 2015
Sales and Marketing Boehringer, Esbriet, Roche, ingelheim, inpulsis, ipd, ofev

Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet …

News
Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
BI image

CHMP nods several drugs through

November 24, 2014
Sales and Marketing Boehringer, CHMP, EMA, Esbriet, FDA, Sanofi, nintedanib, ofev

Ten new medicines have been recommended for approval by the EMA’s Committee for Medicinal Products for Human Use (CHMP), among …

News

Growing IPF drugs market evident at ERS Congress

November 3, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev

Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …

Feature
Boehringer image

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News
ERS event image

InterMune’s IPF drug shines at ERS Congress

September 10, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone

InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …

News
InterMune image

InterMune stock jumps on suitor claims

August 14, 2014
Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune

Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …

News
Esbriet image

Shortlist announced for best new pharma product

June 24, 2014
Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro

Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023